Carla B. Hartman

Carla B. Hartman

Auto-generated profile, based on publicly available information

Carla B. Hartman

Centre of Excellence for Pharmaceutical Sciences North‐West University Potchefstroom South Africa

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
CHCarla B. Hartman
Carla B. Hartman
PDPhelelisiwe S. Dube
Phelelisiwe S. Dube
LLLesetja J. Legoabe
Lesetja J. Legoabe
NPNatascha Van Pelt
Natascha Van Pelt
AMAn Matheeussen
An Matheeussen
RBRichard Mbi Beteck
Richard Mbi Beteck
Several quinoline derivatives incorporating arylnitro and aminochalcone moieties were synthesized and evaluated in vitro against a broad panel of trypanosomatid protozoan parasites responsible for sleeping sickness (Trypanosoma brucei rhodesiense), nagana (Trypanosoma brucei brucei), Chagas disease (Trypanosoma cruzi), and leishmaniasis (Leishmania infantum). Several of the compounds demonstrated significant antiprotozoal activity. Specifically, compounds 2c, 2d, and 4i displayed submicromolar activity against T. b. rhodesiense with half‐maximal effective concentration (EC50) values of 0.68, 0.8, and 0.19 µM, respectively, and with a high selectivity relative to human lung fibroblasts and mouse primary macrophages (∼100‐fold). Compounds 2d and 4i also showed considerable activity against T. b. brucei with EC50 values of 1.4 and 0.4 µM, respectively.